T-cell receptor recognizing HPV58 L1-derived peptides presented by MHC (HPV58 L1-specific TCR)

The T-cell receptor (TCR) recognizing HPV58 L1-derived peptides presented by MHC is an immune receptor that mediates the recognition and destruction of cells infected with Human Papillomavirus type 58 (HPV58) or HPV58-associated malignant cells. HPV58 is a high-risk oncogenic virus particularly prevalent in East Asia and is a significant cause of cervical and other anogenital cancers. The L1 protein is the major capsid protein of the virus and contains several immunogenic epitopes that can be processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, such as HLA-A*11:01 and HLA-A*24:02. TCRs specific for these peptide-MHC (pMHC) complexes are being explored as targets for adoptive T-cell therapies (TCR-T) and therapeutic vaccines. Unlike prophylactic vaccines that induce neutralizing antibodies against L1 virus-like particles (VLPs), TCR-based therapies aim to eliminate established infections or early-stage neoplastic cells by leveraging the cellular immune system. However, the use of L1-specific TCRs in advanced cancer is limited by the frequent loss of L1 expression during viral genome integration into the host DNA. Consequently, these TCRs are primarily investigated for their potential in treating early-stage disease or as part of multi-antigen therapeutic strategies.

Other names

HPV58 L1-specific T-cell receptorHPV58 L1 TCRT-cell receptor recognizing HPV58 L1Human papillomavirus 58 L1-specific TCR

Recognition of HPV58 L1-derived peptides (e.g., HLA-A*11:01 or HLA-A*24:02 restricted) presented by MHC class I molecules on the surface of infected or neoplastic cells, leading to T-cell activation, secretion of effector cytokines (e.g., IFN-gamma), and targeted lysis of the cell.